查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1703477

生物共轭市场－全球产业规模、份额、趋势、机会和预测，按产品（试剂和试剂盒、标籤、其他）、按应用（治疗、研发、诊断）、按地区和竞争细分，2020 年至 2030 年

Bioconjugation Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product (Reagents & Kits, Labels, Others), By Application (Therapeutics, Research & Development, Diagnostics), By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2024 年全球生物共轭市场价值为 17.5 亿美元，预计到 2030 年将达到 25.2 亿美元，预测期内复合年增长率为 6.50%。

市场概览
预测期 2026-2030
2024年市场规模 17.5亿美元
2030年市场规模 25.2亿美元
2025-2030 年复合年增长率 6.50%
成长最快的领域 试剂和试剂盒
最大的市场 北美洲

生物共轭——指两种分子（通常是生物分子和合成化合物）的化学连接——已成为现代医学的变革性技术。由于其增强分子功能的能力，它在製药、生物技术、诊断和生物医学研究等广泛的行业中得到越来越广泛的应用。

该市场的主要成长动力是其在标靶药物传递中的关键作用，其中治疗剂透过化学方式附着于特定的生物标记。这使得能够精确瞄准患病细胞，同时最大限度地减少对健康组织的影响，从而提高疗效并降低毒性。事实证明，这些进步在治疗癌症、自体免疫疾病和传染病方面特别有价值。随着个人化医疗在全球的兴起，对生物结合技术的需求预计将加速成长。

儘管前景光明，但市场仍面临挑战，特别是生物共轭化学的复杂性、高昂的开发成本和监管障碍。然而，化学合成、自动化和先进疗法的需求的持续创新继续加强市场的长期成长轨迹。随着生物共轭技术的发展，它将在下一代治疗和诊断解决方案的进步中发挥越来越重要的作用。

关键市场驱动因素

全球医疗保健产业的扩张

主要市场挑战

生物共轭製程成本高昂

这些成本和资源限制可能会限制小公司的可近性并阻碍其广泛采用，尤其是在早期研发阶段或新兴市场。

主要市场趋势

标靶治疗需求激增

推动生物共轭市场发展的关键趋势是全球对标靶治疗的需求不断增长，特别是在肿瘤学和复杂慢性病管理领域。

目录

第 1 章：产品概述

第二章：研究方法

第三章：执行摘要

第四章：COVID-19 对全球生物共轭市场的影响

第五章：全球生物共轭市场展望

  • 市场规模和预测
    • 按价值
  • 市场占有率和预测
    • 按产品（试剂和试剂盒、标籤、其他）
    • 依应用（治疗学、研发、诊断学）
    • 按地区
    • 按公司分类（2024）
  • 市场地图

第六章：北美生物共轭市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 北美：国家分析
    • 美国
    • 墨西哥
    • 加拿大

第七章：欧洲生物共轭市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 欧洲：国家分析
    • 法国
    • 德国
    • 英国
    • 义大利
    • 西班牙

第八章：亚太生物共轭市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 亚太地区：国家分析
    • 中国
    • 印度
    • 韩国
    • 日本
    • 澳洲

第九章：南美洲生物共轭市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 南美洲：国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第十章：中东与非洲生物共轭市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • MEA：国家分析
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋

第 11 章：市场动态

  • 驱动程式
  • 挑战

第 12 章：市场趋势与发展

  • 合併与收购（如有）
  • 产品发布（如有）
  • 最新动态

第 13 章：全球生物共轭市场：SWOT 分析

第 14 章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的力量
  • 顾客的力量
  • 替代产品的威胁

第 15 章：竞争格局

  • Danaher Corporation
  • Thermo Fisher Scientific Inc.
  • Lonza Group Ltd.
  • Merck KGaA
  • Sartorius AG
  • Abbvie, Inc.
  • Bio-Rad Laboratories, Inc.
  • Agilent Technologies, Inc.
  • Catalent, Inc.
  • Becton, Dickinson and Company

第 16 章：策略建议

第17章调查会社について・免责事项

简介目录
Product Code: 28067

Global Bioconjugation Market was valued at USD 1.75 billion in 2024 and is projected to reach USD 2.52 billion by 2030, growing at a CAGR of 6.50% during the forecast period.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 1.75 Billion
Market Size 2030USD 2.52 Billion
CAGR 2025-20306.50%
Fastest Growing SegmentReagents & Kits
Largest MarketNorth America

Bioconjugation-referring to the chemical linkage of two molecules, typically a biomolecule and a synthetic compound-has emerged as a transformative technique in modern medicine. It is increasingly applied across a broad range of industries, including pharmaceuticals, biotechnology, diagnostics, and biomedical research, owing to its ability to enhance molecular functionality.

A primary growth driver for this market is its pivotal role in targeted drug delivery, where therapeutic agents are chemically attached to specific biomarkers. This enables the precise targeting of diseased cells while minimizing impact on healthy tissue, thereby improving efficacy and reducing toxicity. Such advancements have proven especially valuable in treating cancer, autoimmune disorders, and infectious diseases. With the global rise of personalized medicine, the demand for bioconjugation technologies is expected to accelerate.

Despite its promising outlook, the market faces challenges, particularly the complexity of bioconjugation chemistry, high development costs, and regulatory hurdles. However, ongoing innovations in chemical synthesis, automation, and demand for advanced therapeutics continue to reinforce the market's long-term growth trajectory. As bioconjugation evolves, it is set to play an increasingly central role in the advancement of next-generation therapeutic and diagnostic solutions.

Key Market Drivers

Expansion of the Global Healthcare Industry

The continued growth of the global healthcare sector is a significant catalyst for the bioconjugation market, driving demand for innovative diagnostics and precision therapeutics. Healthcare is among the most rapidly expanding industries worldwide, with expenditures in many developed countries exceeding 10% of GDP. For instance, the United States recorded healthcare spending of USD 4.3 trillion in 2021, accounting for 18.3% of its GDP-approximately USD 12,914 per capita.

As global healthcare systems increasingly prioritize precision medicine, targeted therapies, and advanced diagnostic technologies, bioconjugation has emerged as an enabling platform to enhance treatment efficacy and patient outcomes. In particular, its ability to chemically link biomolecules with functional agents has gained traction in the pharmaceutical and biotech sectors.

The pharmaceutical industry has seen consistent growth, reaching a valuation of approximately USD 1.6 trillion in 2023, comparable to the GDPs of countries like Mexico, Spain, and Australia. This expansion underscores the critical role of bioconjugation in supporting the development of personalized treatment modalities, especially in oncology and chronic disease care.

Antibody-drug conjugates (ADCs) exemplify the growing importance of bioconjugation. These therapies deliver cytotoxic drugs directly to cancer cells, minimizing harm to healthy tissue and improving therapeutic outcomes. As demand for such targeted solutions increases, bioconjugation is becoming a core technology across healthcare applications.

Key Market Challenges

High Costs Associated with Bioconjugation Processes

One of the key obstacles to market growth is the high cost of bioconjugation technologies. The process requires premium-quality raw materials, including antibodies, proteins, and peptides, which are expensive to produce, purify, and stabilize. Additionally, specialized chemical linkers must be carefully selected and optimized to ensure conjugate stability and efficacy-further adding to production expenses.

The requirement for advanced instrumentation also significantly contributes to operational costs. Analytical techniques such as mass spectrometry, chromatography, and high-performance liquid chromatography (HPLC) are essential for validating the conjugation process and analyzing purity and stability. Operating these tools demands both capital investment and a skilled workforce, increasing the overall financial burden on developers of new bioconjugate-based products.

These cost and resource constraints can limit accessibility for smaller companies and hinder widespread adoption, particularly in early-stage R&D or in emerging markets.

Key Market Trends

Surging Demand for Targeted Therapeutics

A key trend propelling the bioconjugation market is the growing global demand for targeted therapies, particularly in oncology and complex chronic disease management.

According to the Global Cancer Observatory (GLOBOCAN), an estimated 19.3 million new cancer cases and nearly 10 million cancer-related deaths occurred globally in 2020. By 2040, cancer incidence is projected to reach 28.4 million cases, representing a 47% increase, largely due to aging populations and lifestyle-related risk factors such as obesity and tobacco use.

This rising burden has amplified the need for more effective treatment options. Targeted therapies-designed to deliver drugs directly to diseased tissues while sparing healthy cells-are becoming the standard of care in many advanced treatment protocols. Bioconjugation is fundamental to the development of such therapies.

Antibody-drug conjugates (ADCs) are among the most prominent bioconjugated solutions in this space, particularly in oncology. By linking potent cytotoxic agents to antibodies that recognize specific cancer cell markers, ADCs offer a high degree of selectivity and efficacy, improving patient outcomes while reducing systemic toxicity.

Key Market Players

  • Danaher Corporation
  • Thermo Fisher Scientific Inc.
  • Lonza Group Ltd.
  • Merck KGaA
  • Sartorius AG
  • Abbvie, Inc.
  • Bio-Rad Laboratories, Inc.
  • Agilent Technologies, Inc.
  • Catalent, Inc.
  • Becton, Dickinson and Company

Report Scope

In this report, the Global Bioconjugation Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Bioconjugation Market, By Product:

  • Reagents & Kits
  • Labels
  • Others

Bioconjugation Market, By Application:

  • Therapeutics
  • Research & Development
  • Diagnostics

Bioconjugation Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Bioconjugation Market.

Available Customizations:

Global Bioconjugation Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, and Trends

4. Impact of COVID-19 on Global Bioconjugation Market

5. Global Bioconjugation Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Reagents & Kits, Labels, Others)
    • 5.2.2. By Application (Therapeutics, Research & Development, Diagnostics)
    • 5.2.3. By Region
    • 5.2.4. By Company (2024)
  • 5.3. Market Map

6. North America Bioconjugation Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Application
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Bioconjugation Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By Application
    • 6.3.2. Mexico Bioconjugation Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By Application
    • 6.3.3. Canada Bioconjugation Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By Application

7. Europe Bioconjugation Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Application
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Bioconjugation Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By Application
    • 7.3.2. Germany Bioconjugation Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By Application
    • 7.3.3. United Kingdom Bioconjugation Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By Application
    • 7.3.4. Italy Bioconjugation Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By Application
    • 7.3.5. Spain Bioconjugation Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By Application

8. Asia Pacific Bioconjugation Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Application
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Bioconjugation Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By Application
    • 8.3.2. India Bioconjugation Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By Application
    • 8.3.3. South Korea Bioconjugation Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By Application
    • 8.3.4. Japan Bioconjugation Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By Application
    • 8.3.5. Australia Bioconjugation Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By Application

9. South America Bioconjugation Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Application
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Bioconjugation Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By Application
    • 9.3.2. Argentina Bioconjugation Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By Application
    • 9.3.3. Colombia Bioconjugation Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By Application

10. Middle East and Africa Bioconjugation Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By Application
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Bioconjugation Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By Application
    • 10.3.2. Saudi Arabia Bioconjugation Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By Application
    • 10.3.3. UAE Bioconjugation Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By Application

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Bioconjugation Market: SWOT Analysis

14. Porters Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Danaher Corporation
    • 15.1.1. Business Overview
    • 15.1.2. Company Snapshot
    • 15.1.3. Products & Services
    • 15.1.4. Financials (As Reported)
    • 15.1.5. Recent Developments
    • 15.1.6. Key Personnel Details
    • 15.1.7. SWOT Analysis
  • 15.2. Thermo Fisher Scientific Inc.
  • 15.3. Lonza Group Ltd.
  • 15.4. Merck KGaA
  • 15.5. Sartorius AG
  • 15.6. Abbvie, Inc.
  • 15.7. Bio-Rad Laboratories, Inc.
  • 15.8. Agilent Technologies, Inc.
  • 15.9. Catalent, Inc.
  • 15.10. Becton, Dickinson and Company

16. Strategic Recommendations

17. About Us & Disclaimer